K67

K67 is a selective the interaction between Keap1 and S349 phosphorylated p62 inhibitor, with an IC50 of 1.5 μM. K67 has a weaker inhibitory effect on the interaction between Keap1 and Nrf2 (IC50 is 6.2 μM) . K67 competitively binds to the binding site of Keap1 with p-p62, blocking the abnormal activation of the p62-dependent Nrf2 pathway. K67 inhibits tumor cell proliferation and enhances the sensitivity of hepatocellular carcinoma (HCC) to chemotherapeutic drugs by restoring Keap1-mediated ubiquitination and degradation of Nrf2[1][2].

Product Specifications

CAS Number

[2046250-48-8]

UNSPSC

12352005

Target

Keap1-Nrf2; p62

Type

Reference compound

Related Pathways

Autophagy; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/k67.html

Purity

98.26

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(CC1=CC(NS(C2=CC=C(C=C2)OCC)(=O)=O)=C3C=CC=CC3=C1NS(C4=CC=C(C=C4)OCC)(=O)=O)=O

Molecular Formula

C29H30N2O7S2

Molecular Weight

582.69

References & Citations

[1]Saito T, et al. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun. 2016 Jun 27;7:12030.|[2]Yasuda D, et al. Synthesis of Keap1-phosphorylated p62 and Keap1-Nrf2 protein-protein interaction inhibitors and their inhibitory activity. Bioorg Med Chem Lett. 2016 Dec 15;26 (24) :5956-5959.